# Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.

> **NCT04453423** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 90 (estimated)

## Conditions studied

- Non-squamous Non-small-cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib + Pemetrexed+Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Anlotinib + Pemetrexed
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04453423
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-01
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2020-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04453423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04453423, "Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04453423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*